Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 10/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1378651 | 0.92 | KCNA5 (0.47) | KCNA5KCNH2VNN1CYP19A1CHRNB2 | |
| SCHEMBL1380955 | 0.90 | CYP19A1 (0.46) | KCNA5KCNH2VNN1CYP19A1CHRNB2 | |
| Ammonia Solution, Strong SCHEMBL27668110 | 0.89 | KCNA5 (0.38) | KCNA5KCNH2VNN1CYP19A1CHRNB2 | |
| SCHEMBL3886787 | 0.88 | KCNA5 (0.45) | KCNA5KCNH2VNN1CYP19A1CHRNB2 | |
| SCHEMBL3898283 | 0.87 | KCNA5 (0.44) | KCNA5KCNH2VNN1CYP19A1CHRNB2 | |
| SCHEMBL3894888 | 0.87 | CHRNB2 (0.41) | KCNA5KCNH2VNN1CYP19A1CHRNB2 | |
| SCHEMBL1381135 | 0.86 | KCNA5 (0.54) | KCNA5KCNH2 | |
| SCHEMBL1379399 | 0.86 | KCNA5 (0.54) | KCNA5KCNH2 | |
| SCHEMBL3886070 | 0.85 | KCNA5 (0.53) | KCNA5KCNH2 | |
| SCHEMBL15014678 | 0.85 | KCNA5 (0.53) | KCNA5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776355-B1 | POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2013-06-12 | — | — | EP | claimed |
| JP-4719744-B2 | — | — | 2011-07-06 | — | — | JP | claimed |
| EP-1776355-A4 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2009-08-12 | — | — | EP | claimed |
| EP-1776355-A2 | POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2007-04-25 | — | — | EP | claimed |
| US-20060030595-A1 | (R)-N-{6-[1-(4-fluorophenyl)-2,2-dipyridin-3-ylethyl]pyridin-2-yl}methanesulfonamide; cardiac arrhythmias | MERCK SHARP & DOHME LLC | 2006-02-09 | — | — | US | claimed |
| WO-2006014877-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | claimed |
| EP-1776355-B1 | POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2013-06-12 | — | — | EP | disclosed |
| EP-1776355-B1 | POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2013-06-12 | — | — | EP | disclosed |
| US-7569589-B2 | Potassium channel inhibitors | MERCK & CO., INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569589-B2 | Potassium channel inhibitors | MERCK & CO., INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569589-B2 | Potassium channel inhibitors | MERCK & CO., INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20060030595-A1 | (R)-N-{6-[1-(4-fluorophenyl)-2,2-dipyridin-3-ylethyl]pyridin-2-yl}methanesulfonamide; cardiac arrhythmias | MERCK SHARP & DOHME LLC | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030595-A1 | (R)-N-{6-[1-(4-fluorophenyl)-2,2-dipyridin-3-ylethyl]pyridin-2-yl}methanesulfonamide; cardiac arrhythmias | KCNN2, KCNJ2, KCNH2 | KCNA5 14/4885KCNH2 3/4885VNN1 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.